publication date: Nov. 29, 2016

NCI CTEP-Approved Trials for November

NCI CTEP approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I          9910

A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor 

University Health Network Princess Margaret

Cancer Center LAO

Bradbury, Penelope Ann

(416) 946-4522

 

Phase II         9775

A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Mayo Clinic Cancer Center LAO

Al-Kali, Aref

(507) 538-0591

 

Phase II         9780

A Phase 2 Study of MLN0128 (TAK-228) in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations

Memorial Sloan Kettering Cancer Center

Paik, Paul K.

(212) 639-4013

 

Phase II         S1512

A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)

SWOG

Continue reading CCL Nov 2016 – NCI CTEP-Approved Trials for November

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.